Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Hydromorphone HCI Injection, USP, CII (2 mg\/mL) 1mg\/mL Vial and four lots of Levophed\u00ae (Norepinephrine Bitartrate Injection, USP), 4 mg\/4 mL (1 mg\/mL) Vial due to a potential lack of sterility assurance resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process. To date, Hospira, Inc., a Pfizer company has not received any reports of adverse events related to this recall.<\/p>\n","protected":false},"excerpt":{"rendered":"
Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Hydromorphone HCI Injection, USP, CII (2 mg\/mL) 1mg\/mL Vial and four lots of Levophed\u00ae (Norepinephrine Bitartrate Injection, USP), 4 mg\/4 mL (1 mg\/mL) Vial due to a potential lack of sterility assurance resulting from use of a damaged sterilizing filter for nitrogen used in … Continue reading Hospira Issues Voluntary Worldwide Recall For Lots of Hydromorphone HCl Injection, USP, CII, (2 mg\/mL) 1mg\/mL Vial, and Levophed\u00ae (Norepinephrine Bitartrate Injection, USP), 4 mg\/4 mL (1 mg\/mL) Vial, Due to a Lack of Sterility Assurance<\/span>